pharmaphorum

AUGUST 10, 2021

Europe market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according to Andrew Obenshain, president of its severe genetic diseases unit. On the firm’s second-quarter results call, Obenshain said the biotech will start “an orderly wind-down” of its activities in Europe and seek “strategic alternatives” to make its therapies available to patients there

135

135

Outsourcing Pharma

AUGUST 9, 2021

Nanomeâs virtual reality tech is being put to use by Oak Ridge National Laboratory and top pharma firms to study COVID-19 and explore drug candidates.

136

136

Pharma in Brief

AUGUST 9, 2021

On July 31, 2021, Health Canada published a Notice of Intent outlining its plan to amend the Food and Drug Regulations ( FDR ) and the Medical Devices Regulations in the spring of 2022. The proposed amendments are intended to modernize the Canadian therapeutic product regulatory system at every stage of products’ lifecycles from authorization to post-market.

Labelling 98

Labelling Packaging Biosimilars 98

Pharma Marketing Network

AUGUST 11, 2021

Tune in with the Pharma Marketing Network for an insightful conversation with R.J. Lewis and Diane Bartoli, VP and General Manager of epocrates, as she shares her background with eCME, how COVID-19 has been driving it’s rapid growth, the other digital channels that have come into play, the term “snackable eCME” and how we can expect eCME to trend in a post-COVID sense.

97

97

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

AUGUST 10, 2021

Oxford University and UK clinical artificial intelligence (AI) company Sensyne Health will partner on a project to find new drug targets for people with hard-to-treat asthma. It’s estimated that almost one in five people with asthma find it difficult to control symptoms using current therapies, while around 4% have particularly severe forms that puts them at risk of life-threatening attacks.

Hospitals 113

Hospitals 113

Outsourcing Pharma

AUGUST 10, 2021

The US-based company continues its move away from smoking products with the purchase of drug developer OtiTopic, as part of its Beyond Nicotine initiative.

Drug Development 114

Drug Development 114

NY Times

AUGUST 9, 2021

The author discusses his psychedelic journey and why the government embraces some drugs while waging a war against others.

90

90

pharmaphorum

AUGUST 10, 2021

BioNTech has suggested that giving booster doses of its current Comirnaty (BNT162b2) COVID-19 vaccine may be a preferable strategy to modifying the Pfizer-partnered shot. The comments came on the German biotech’s second-quarter results call, during which BioNTech raised its forecasts for revenues it will book from sales of the vaccine to €15.9 billion (almost $19 billion), on the back of contracts to deliver 2.2 billion doses this year with more than 1 billion already booked in for 2022.

Vaccines 111

Vaccines Immunity Immunization 111

Outsourcing Pharma

AUGUST 9, 2021

A leader from Longboat by Advarra outlines what it really means for a study to be patient centric, and how to succeed in achieving patient-centric trials.

111

111

Pharma Times

AUGUST 11, 2021

US biotech company says European payers have ‘not yet evolved their approach to gene therapy’

117

117

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

NY Times

AUGUST 12, 2021

Jazz Pharmaceuticals brought in more than $1.7 billion last year selling GHB to narcolepsy patients. With the new approval, sales could soar.

69

69

pharmaphorum

AUGUST 12, 2021

With advertisers preparing to spend up to $15 billion on influencer marketing by 2022, pharmaceutical and biotech companies are increasingly (and carefully) engaging trusted health social influencers to connect more authentically with consumers. As pharma starts to leverage a multitude of high-engagement channels like influencer marketing, online communities and virtual health services, the industry finds itself in a unique position to reimagine traditional direct-to-consumer (DTC) efforts and p

Communication 109

Communication 109

Outsourcing Pharma

AUGUST 10, 2021

The University of Illinois at Chicago has been given $6m from the US Department of Defense to develop a potential treatment for severe cases of COVID-19.

111

111

Pharma Times

AUGUST 12, 2021

Combination treatment reduced the risk of disease progression or death by 61% versus Sutent

123

123

Drug Channels

AUGUST 11, 2021

The Medicare Payment Advisory Commission (MedPAC), the independent agency that advises Congress on the Medicare program, recently released its latest Health Care Spending and the Medicare Program databook. This annual report is a treasure trove of useful and fascinating data. The July 2021 edition provides us with the latest pre-pandemic details on the buy-and-bill market in Medicare Part B.

Hospitals 58

Hospitals 58

pharmaphorum

AUGUST 9, 2021

AstraZeneca’s Forxiga has become the first SGLT2 inhibitor to be approved in Europe for use in people with chronic kidney disease, extending its lead over rival drugs in the class. The European Commission has cleared Forxiga (dapagliflozin) for CKD in adults with or without diabetes, and the drug becomes the first new drug treatment for these patients in more than two decades.

Diabetes 109

Diabetes 109

Outsourcing Pharma

AUGUST 11, 2021

The US Food and Drug Administration has kept its staff busy with approvals, authorizations, and warnings related to various coronavirus-centered products.

98

98

Pharma Times

AUGUST 12, 2021

The 2021 Communications Awards will be closing its doors for entry on the 10th of September.

Communication 123

Communication 123

Drug Channels

AUGUST 13, 2021

Today’s guest post comes from Stacey Little, Senior Vice President of Business Development and Marketing at AssistRx. Stacey discusses how a patient support vendor can help specialty pharmacy patients attain prior authorizations and access critical therapies. She offers three criteria that manufacturers can use to evaluate e-support services providers.

Specialty Pharmacies 54

Specialty Pharmacies 54

pharmaphorum

AUGUST 12, 2021

The UK government has started ordering COVID-19 vaccines for a 2022 booster campaign, including a 32 million-dose order for the Pfizer/BioNTech shot, even before third doses for 2021 have been given the go-ahead. A report in The Times claims that the government is paying £22 a dose – up from an earlier price of £18 – for the Pfizer/BioNTech vaccine as part of a £1 billion deal for additional supplies, which is needed because existing stocks will be depleted next year.

Vaccines 109

Vaccines Immunity Immunization 109

Outsourcing Pharma

AUGUST 12, 2021

The World Health Organizationâs Solidarity PLUS trial will kick off in 52 countries, trialing three drugs to treat patients hospitalized with COVID-19.

Hospitals 98

Hospitals 98

Pharma Times

AUGUST 9, 2021

The 2021 Marketer of the Year competition will be closing for entry on the 10th of September.

122

122

Drug Patent Watch

AUGUST 13, 2021

Annual Drug Patent Expirations for PRADAXA Pradaxa is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from three suppliers. There are five patents…. The post New patent for Boehringer Ingelheim drug PRADAXA appeared first on DrugPatentWatch - Make Better Decisions.

52

52

pharmaphorum

AUGUST 11, 2021

Merck & Co is looking at a decision from the FDA in December on its application to market Keytruda as a post-surgery treatment for people with kidney cancer, after a priority review. The drugmaker – known as MSD outside the US and Canada – is seeking approval of Keytruda (pembrolizumab) as an adjuvant treatment for renal cell carcinoma (RCC) patients who have undergone surgery for the cancer and are at risk of relapse.

108

108

Outsourcing Pharma

AUGUST 10, 2021

The pharma firm is working with five US colleges and universities onto create programming designed to boost recruitment of Black talent in the industry.

92

92

Pharma Times

AUGUST 9, 2021

Trial compared Enhertu with T-DM1 in patients with HER2-positive breast cancer

129

129

Drug Patent Watch

AUGUST 13, 2021

Annual Drug Patent Expirations for CAPRELSA Caprelsa is a drug marketed by Genzyme Corp and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent expiration for Genzyme Corp drug CAPRELSA appeared first on DrugPatentWatch - Make Better Decisions.

52

52

pharmaphorum

AUGUST 9, 2021

Australian telecommunications giant Telstra has reached a deal to acquire MedicalDirector, a company specialising in software used by GPs to manage their practices. Telstra Health – the Australian group’s digital health arm – is paying A$350 million ($257 million) to buy MedicalDirector from investment company Affinity Equity Partners, which bought the company from former owner Healius for A$155 million in 2016.

Hospitals 104

Hospitals 104

Outsourcing Pharma

AUGUST 12, 2021

The Heart of Athletes study, using Deloitteâs ConvergeHealth MyPath for Clinical platform, aims to examine heart inflammation in athletes with the virus.

64

64

Pharma Times

AUGUST 11, 2021

Collaboration will drive medicines discovery in areas of unmet patient need

129

129

Pharma Marketing Network

AUGUST 13, 2021

Sunny drives the promotion of global brands for pharmaceutical, biotech and medical. device. She founded Xavier Creative House (XCH), a healthcare marketing agency that. builds BOLD and EVOCATIVE designs, pushing the edge of creativity. Sunny is the point person for positioning your brand into a “Powerhouse.” As, CEO, she leads Operations and Client Management utilizing a wealth of experience gained from her roles in communications, compliance, and sales in rapid-growth companies.

Communication 52

Communication 52

pharmaphorum

AUGUST 13, 2021

Israeli femtech start-up GinaLife is developing a platform of biomarker strategies supported by artificial intelligence and data science for the early detection of problems in women’s health. CEO and co-founder Inbal Zafir-Lavie tells pharmaphorum more. Six years ago, research scientist Inbal Zafir-Lavie tragically lost her 38-year-old sister Hava Zafir to colorectal cancer.

103

103

Drug Patent Watch

AUGUST 12, 2021

Annual Drug Patent Expirations for XOFLUZA Xofluza is a drug marketed by Genentech Inc and is included in two NDAs. It is available from two suppliers. There are six patents…. The post New patent for Genentech Inc drug XOFLUZA appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Pharma Times

AUGUST 13, 2021

First and only FDA-approved treatment for the neurological sleep disorder

129

129

Outsourcing Pharma

AUGUST 9, 2021

A leader from Tools4Patient discusses the importance understanding ties between the two in reducing the impact of the placebo response in clinical trials.

52

52